All members have the option of attending our various HTC-centric events which include:
Date: Thursday, January 15th, 2026
Time: 1:00pm – 2:00pm ET
WEBINAR TITLE:
Five-Year Analysis: Efficacy and Safety of HEMGENIX®
Presentation of the published efficacy and safety results of the five-year analysis of the HOPE-B clinical trial follow up.
Vidhi Desai, Senior Medical Director (Coagulation), US Medical Affairs
Vidhi Desai joined CSL Behring in 2018 as Therapeutic Area Head, Director Medical Affairs for Coagulation Products in North America, providing strategic and tactical medical leadership for Hemgenix®, Idelvion®, Afstyla® and Humate-P®, contributing to key operational and cross-functional projects as a member of the Medical Affairs leadership team.
Prior to joining CSL Behring, Vidhi worked as an attending hematologist at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, focusing primarily on benign hematologic disorders.
Vidhi earned her Doctor of Medicine at New York Medical College and completed her internal medicine and hematology/oncology training at Rutgers Robert Wood Johnson Medical School in New Brunswick, NJ.
